A heparin-binding activity on Leishmania amastigotes which mediates adhesion to cellular proteoglycans by unknown
A Heparin-binding Activity on Leishmania Amastigotes 
Which Mediates Adhesion to Cellular Proteoglycans 
Dona C. Love, Jeffrey D. Esko,* and David M. Mosser 
Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, Pennsylvania 19140; and 
*  Department of Biochemistry, Schools of Medicine and Dentistry, University of Alabama at Birmingham, Birmingham, 
Alabama 35294 
Abstract.  The intracellular  amastigote form of leish- 
mania is responsible for the cell-to-cell spread of 
leishmania infection in the mammalian host.  In this 
report,  we identify a high-affinity,  heparin-binding  ac- 
tivity on the surface of the amastigote form of leish- 
mania.  Amastigotes of Leishmania  amazonensis bound 
approximately  120,000 molecules of heparin per cell, 
with a Kd of 8.8  ×  10  -s M.  This heparin-binding  ac- 
tivity mediates the adhesion of amastigotes to mam- 
malian cells via heparan sulfate proteoglycans, which 
are expressed on the surface of mammalian cells. 
Amastigotes bound efficiently to a variety of adherent 
cells which express cell-surface proteoglycans.  Unlike 
wild-type CHO cells, which bound amastigotes avidly, 
CHO cells with genetic deficiencies in heparan sulfate 
proteoglycan biosynthesis or cells treated with 
heparitinase failed to bind amastigotes even at high 
parasite-input dosages. Cells which express normal 
levels of undersulfated heparan bound amastigotes 
nearly as efficiently as did wild-type cells.  The adhe- 
sion of amastigotes to wild-type nonmyeloid cells was 
almost completely inhibited by the addition of 
micromolar amounts of soluble heparin or heparan 
sulfate but not by the addition of other sulfated poly- 
saccharides.  Binding of amastigotes to macrophages, 
however, was inhibited by only 60 % after pretreatment 
of amastigotes with heparin,  suggesting that macro- 
phages have an additional mechanism for recognizing 
amastigotes.  These results suggest that leishmania 
amastigotes express a high-affinity,  heparin-binding  ac- 
tivity on their surface which can interact with heparan 
sulfate proteoglycans on mammalian  cells.  This inter- 
action may represent an important first step in the in- 
vasion of host cells by amastigotes. 
EISHMANIA are dimorphic intracellular  protozoan para- 
sites. The flagellated promastigote form is delivered 
to the mammalian host from an infected sandfly. This 
developmental  form invades mammalian cells and quickly 
transforms  to the intracellular  amastigote  form.  It is  the 
amastigote  form of the parasite which replicates  in mam- 
malian  cells (20) and spreads  the infection  to neighboring 
cells. 
A great deal of information  concerning the interaction  of 
the promastigote form with mammalian  macrophages  has 
been compiled (28). Promastigotes bind to specific receptors 
on macrophages and  enter cells by receptor-mediated en- 
docytosis (22).  Several  groups have demonstrated that the 
macrophage is the primary,  if not exclusive, cell infected by 
promastigotes (8). The binding  of promastigotes to macro- 
phages involves a variety  of apparently redundant  mecha- 
nisms. Both complement and lectin-like receptors have been 
shown to participate  in this interaction  (3, 21). The coexpres- 
sion  of complement  and  lectin-like  receptors  on  macro- 
phages may define the cell type specificity  of promastigote 
invasion. In contrast to promastigotes,  little is known about 
how the amastigote  form interacts  with mammalian  cells. 
Neither the amastigote  surface structures involved in para- 
site  adhesion  nor  the  receptors  on  mammalian  cells  for 
amastigotes  have  been  identified.  The  cell  specificity  of 
amastigote  binding  also remains  largely  undefined.  Unlike 
the promastigote form, whose infectivity  appears to be re- 
stricted to macrophages  (17), amastigotes  have been shown 
to infect fibroblasts  in vitro (7,  10). Furthermore,  in leish- 
mania lesions,  intact  amastigotes  can be found within both 
macrophages and nonmyeloid cells (32). Despite the fact that 
amastigotes are the developmental form found in the infected 
host  and  the  form  responsible  for spreading  the  disease 
within  the host, little  is known about the molecular struc- 
tures used during  parasite adhesion and invasion. 
Most animal  cells express proteoglycans.  Proteoglycans 
consist of a protein core which contains one or more cova- 
lently  attached  glycosaminoglycan  (GAG)  ~ chains.  GAGs 
are linear polysaccharides that consist of repeating disaccha- 
ride units bearing a net negative charge (15). The most corn- 
1. Abbreviations used in this paper: GAG, glycosaminoglycan; MPM, mu- 
rine peritoneal macrophages; PB, phagocytosis buffer; PD, cation-free Dul- 
becco's PBS. 
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sulfate, dermatan sulfate, and heparan sulfate. Heparin is 
very similar to heparan sulfate, except it is more highly sul- 
fated, contains a higher proportion of iduronic acid, and is 
only produced by connective tissue mast cells. Proteoglycans 
can be anchored to the plasma membrane and expressed on 
the surface of cells (11). They can also be secreted from cells 
and deposited in the extracellular matrix, or they can be 
found intracellularly in secretory granules.  Proteoglycans 
have many physiological functions, some of which are the 
mediation of cell/cell and cell/extracellular matrix interac- 
tions, the maintenance of tissue integrity, and the sequestra- 
tion of growth factors near the cell  surface (16). Recent 
reports have indicated that GAGs provide a mechanism of ad- 
herence for several human pathogens. Chlamydia trachoma- 
tis express heparan sulfate-like GAGs which mediate cellular 
attachment to eukaryotic host cells (31). Herpes simplex vi- 
rus (29) and cytomegaiovirus (25) bind to heparan sulfate 
proteoglycans  on  mammalian  ceils,  and  this  interaction 
represents the first step in viral infection. Recently, heparan 
sulfate proteoglycans, localized on the basolateral domain of 
hepatocytes, have been identified as a receptor for the ma- 
laria circumsporozoite protein (6,  27).  A  heparin-binding 
protein has also been identified on Trypanosoma cruzi (26). 
This molecule is believed to aid in migration of the organism 
through the extraceUular matrix by attaching to extracellular 
matrix components. 
In this report, we identify a high-affinity, heparin-binding 
activity on the surface of leishmania amastigotes. We pro- 
pose that this activity mediates attachment of amastigotes to 
mammalian cells by binding to cellular proteoglyeans con- 
taining heparan sulfate. 
Materials and Methods 
Parasites 
The U.S. National Institutes of Health S strain of Leishmania major (2) was 
isolated from a West African patient with cutaneous leishmaniasis and was 
originally provided IV Dr. David Wyler (Tufts University Medical Center, 
Boston, MA). The Josefa isolate ofLeishmania mexicana wrgtz~nensis (23) 
was isolated from a Brazilian patient with persistent cutaneous leishmania- 
sis and was provided IV Dr. Janet Keithly (New York State Public Health 
Center, Albany, NY). Promastigotes were cultured in Schneider's complete 
medium containing Schneider's Drosophila  medium (GIBCO-BRL, Gai- 
thersburg, MD) supplemented with 20%  FCS, penicillin G/streptomycin 
(100 U/ml and 100 ttg/ml, respectively), and 2 mM glutamine. Stationary- 
phase promastigotes were radiolabeled overnight with [3H]uracil  as de- 
scribed (21). Amastigotes were isolated from the footpad of BALB/c mice 
which were infected 6 to 8 wk earlier as described (20). Briefly, the excised 
foot was forced through a wire mesh using the plunger from a 10-ml syringe 
while washing with 10 ml Schneider's complete medium. The mixture was 
then subjected to repeated passages through 21-, 23-, and 25-gauge needles 
to release the amastigotes from host cells. Cellular debris was removed from 
the mixture IV centrifugation at 50 g for 5 rain. Amastigotes were incubated 
in Schneider's medium on ice for 60 min to allow any associated cellular 
debris to detach. Amastigotes were then sedimented IV centrifugation at 
600 g for 10 rain. FOr cell-binding assays, amastigotes were resuspended 
in an isotonic phagocytosis buffer (PB) which consists of equal parts of 
medium 199 and DME buffered with 12.5 mM Hepes (Mediatech, Hem- 
don,  VA)  (21).  FOr  radiolabeling,  amastigotes  were  added  to  the 
macrophage-like cell line J-774A.1, and the infected cells were incubated 
with [3H]uracil  as described (20). 
Cells 
Several mutant CHO cells with specific deficiencies  in proteoglycan biosyn- 
thesis were used. Mutants pgsA-745 and pgsB-618 lack xylosyltransferase 
and galactosyltransferase I, respectively, enzymes necessary for the initia- 
tion of  GAG biosynthesis (13, 14). Mutant pgsD-677 does not express hepa- 
ran sulfate, but overexpresses chondroitin sulfate IV a factor of three, caus- 
ing the total amount of sulfated glycosaminoglycan  to be comparable to that 
of wild-type cells (18). The mutant cell line pgsE-606 has reduced N-sulfo- 
transferase activity which results in undersnifation of heparan sulfate with- 
out altering the levels of GAG synthesis (1). CHO-K1 and mutant CHO cells 
were maintained in Ham's F12 medium (GIBCO-BRL) supplemented with 
10%  FCS, penicillin G/streptomycin (100  U/ml and  100/~g/ml,  respec- 
tively), and 2 mM L-glutamine (GIBCO-BRL). HEp-2 human epidermoid 
carcinoma cells, NIH-3T3 cells, and L-929 cells (American Type Culture 
Collection, Rockville, MD) were maintained in DME supplemented with 
10%  FCS, penicillin G/streptomycin (100  U/ml and  100  #g/ml,  respec- 
tively), and 2 mM L-glutamine (D-10). Human foreskin fibroblast cells were 
obtained from 2-d-old males and were provided IV Dr.  Earl Hendersen 
(Temple University School of Medicine, Philadelphia, PA).  Human fore- 
skin fibroblast cells were maintained in D-10. The macrophage-like cell line 
J-774A.1  (ATCC)  was maintained in DME supplemented with 7% FCS, 
penicillin G/streptomycin (100 U/nil and 100/~g/ml, respectively), and 2 
mM  L-glutamine  (D-7).  Murine  peritoneal  macrophages  (MPM)  were 
washed from the peritoneal cavity of BALB/c mice with cold cation-free 
Dulbecco's pbospbate-buffered saline (PD) as previously described (21). 
Cells were washed with DME and incubated overnight on glass coverslips 
in D-7. Mononuclear cells were isolated from human peripheral blood using 
Lymphoprep (Nycomed Phara, Osio, Norway) according to the manufac- 
turer's instructions (24).  Ceils were resuspended in RPMI-1640  (Medi- 
atech) and adhered to 13-mm glass coverslips in 24-well plates for 30 min 
at 37°C. After washing, the monocytes were used immediately. Before use 
in binding assays, all monolayers were washed free of serum. All binding 
assays were performed in PB. 
Amastigote-binding Assay 
Cells were incubated on 13-ram glass coverslips in 24-well plates overnight 
in medium containing FCS. Monolayers were washed three times with PB 
before use, and then amastigotes were added to the monolayers in PB at the 
indicated concentrations. The amastigotes were allowed to bind to the 
monolayers for 45 min at 35°C. All binding studies were carried out in a 
total volume of  400-t~l per well. After the incubation, the cells were washed 
at  least three times with  PB to  remove unbound amastigotes from the 
monolayer. The monolayers were then fixed with 2.5 % glutaraldehyde in 
PD, stained with Giemsa dye, and bound organisms on triplicate coverslips 
were quantitated IV light microscopy. One hundred cells were counted per 
coverslip. For the radiobinding assay,  monolayers were solubilized with 
0.5%  Triton X-100 for 30 rain, transferred to scintillation vials, and the 
amount of radiolabel present was quantitated IV a TRI-CARB 1900 CA liq- 
uid scintillation analyzer (Packard, Sterling, VA). 
To inhibit the binding of amastigotes to cells, either the amastigotes were 
pretreated with competitors for 20 min on ice and washed two times before 
their addition to the monolayers, or inhibitors and amastigotes were simul- 
taneonsly added to the monolayers and left in throughout the 45-min assay. 
The competitors used were hyaluronic acid (Sigma Immunochemicals, St. 
Louis, MO), beparin, chondroitin sulfate (Calbiochem-Behring Corp., San 
Diego, CA) and heparan sulfate isolated from bovine aorta as described 
(12). Enzymatic treatment of cells was performed according to Neyts et al. 
(25).  Briefly,  heparitinase  (Seikaocalru America,  I/.ockville,  MD)  was 
resuspended in medium 199 +  0.1% BSA. The monolayers were treated for 
2 h at 370C and washed three times with medium 199  +  0.1% BSA. The 
monolayers were then used in binding assays as described above. 
Heparin-radiobinding Assay 
Freshly isolated, washed amastigotes were incubated on ice for 1 h in PB 
before the binding assay. The washed amastigotes were resuspended in fresh 
PB containing 0.5 % BSA. Increasing amounts of radiolabeled beparin were 
added to a total of 2  x  107 amastigotes. In some experiments, unlabeled 
competitors were also included. The amnstigotes were incubated with ra- 
diolabeled heparin for 30 rain at 4oc. After this incubation, amastigotes 
were washed four times in PB containing 1% BSA. In some experiments 
free lZSl-labeled heparin was separated from bound I~I-labeled heparin I  V 
layering the parasites on an oil gradient consisting of one part bis phthalate 
and one and a half parts dibutyl phthalate (Eastman Kodak Co., Rochester, 
NY).  The  radioactivity bound to  amastigotes was  determined using  a 
Gamma trac 1191 automatic gamma counting system (Tracer Analytic, Elk 
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activity was compared to the amount of non.specific binding defined as the 
binding which occurred in a t00-fold excess of unlabeled heparin. Heparin 
was radiolabeled according to Cardin et al. (5). Briefly, 2.5 mg of heperin 
was  reacted  with  1 rag  of BoRon-Hunter reagent (N-succinimidyl-3(4-  40 
hydroxyphenyl)propionate) (Pierce, Rockford, IL) in 0.5 ml of  0.1 M borate 
buffer, pH 9.0, for 20 rain on ice. The unreacted, insoluble BoRon-Hunter 
reagent was removed by centrifugation for 30 s at 12,000 g. The sample was  "~ 
then reacted with 1 nag of fresh BoRon-Hunter reagent for 20 min. The un-  ~.  3o 
reacted BoRon-Hunter reagent was separated from the derivatized heparin  o  OD 
by passing the sample over a PD-10 column (Pharmacia Fine Chemicals, 
Piscataway,  NJ). Fractions (0.5 ml) were collected and analyzed for heparin  o_ 
C9  20 
content according to Macintosh (19).  Fractions containing heparin were  "o 
then added to  lodo-vials containing two Iodobeads (Pierce).  1  t~Ci of 
carrier-free Nal~I (Amersham Corp., Arlington Heights, IL) was added to 
the vial. The reaction was allowed to proceed for 15 rain at room tempera-  ~0 I 
ture and was terminated by removing the sample from the vial. Free Nat25I 
was removed by passage over a PD-IO column which had been equilibrated 
with PD. The radiolabeled heparin was eluted with PD, and the fractions 
containing radiolabeled heparin were determined using a 3' counter. The 
concentration of heparin recovered from the procedure was determined as 
described above. 
Dot Blot Assay 
Approximately 1  X  109 L. amazonensis amastigotes were solubilizad in 1 
ml  of lysis buffer containing 0.5%  Triton X-100,  25  mM KCI,  5  mM 
MgCl2, and 5  mM Tris,  pH 7.5.  The following protease inhibitors were 
added to the lysis buffer: leupeptin (0.5  #g/ml); aprotinin (1 #g/ml); soy 
bean trypsin inhibitor (50 t~g/mi); PMSF (1.0 mM); and 1,10-phenanthro- 
line (2 mM). Amastigotes were solubillzed on ice for 30 min. Insoluble pro- 
tein was removed by centrifugation at 12,000 g for 10 rain. Soluble protein 
was removed and either used immediately or stored for up to  1 wk at 
-20"C.  Soluble  amastigote  protein  was  blotted  onto  nitrocellulose 
(Schleicher & Sehuell, Keene, NH) as described (30), using a vacuum man- 
ifold dot blot apparatus. The nitrocellulose was previously washed with PD, 
100 ttl per well. After addition of lysate, each well was washed with 300 
#1 of PD. After incubation for I h at room temperature, the blot was blocked 
for 15 rain with 0.15 M NaCI, 0.1 M Tris-HCl, pH 7.3, 1 mg/ml BSA, and 
0.05 % Tween 20.  Next, the blot was placed in a sealable bag containing 5 
ml of the same buffer and incubated with radiolabeled heperin for 30 rain 
at room temperature. Blots were washed three times with blocking buffer, 
30 rain per wash. The blots were air dried and exposed to a Fuji imaging 
plate for 1 h and visualized using a Fuji Bio-imager (Stamford, CT). 
Results 
The Binding of  Amastigotes to Mammalian Cells 
Increasing  concentrations of radiolabeled L.  amazonensis 
amastigotes were added to murine peritoneal macrophages 
for 45 rain at 350C in the absence of exogenous serum. Un- 
der these conditions,  amastigotes bound avidly to macro- 
phages and withstood vigorous washing. Amastigotes bound 
to macrophages in a dose-dependent manner (Fig.  1). The 
efficiency of amastigote binding in vitro was defined as the 
number of parasites added per cell required to achieve one 
organism bound per cell. This binding efficiency, calculated 
at multiple parasite-input doses, was 7.0 +  1.25 (SEM, n  = 
16). In this in vitro model, this efficiency  is between two- and 
fivefold greater than that of the binding of the promastigote 
form of  leishmania to macrophages (21). Leishmania amasti- 
gotes were also added to parallel monolayers of the murine 
fibroblastoid cell line L-929. These cells also bound amasti- 
gotes in a dose-dependent manner (Fig.  1), but the relative 
efficiency of this binding was approximately threefold lower 
than the efficiency with which macrophages bound arnasti- 
gotes. Thus, the efficiency of amastigote binding to L-929 
cells was comparable to the efficiency of promastigote bind- 
ing to macrophages. 
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Figure 1.  A comparison of the binding of L. amazonenis amas- 
tigotes to macrophage and nonmacrophage cells. Increasing num- 
bers of radiolabeled L. amazonensis amastigotes were added to 
monolayers of either mouse peritoneal macrophages (o) or L-929 
cells (o). Binding proceeded for 45 min at 35°C. Monolayers were 
washed three times, solubilized in Triton X-100, and the amount of 
radioactivity associated with the monolayers was determined using 
a B-counter. Data represent the average of two determinations. The 
experiment shown is representative of three experiments. Amas- 
tigotes were radiolabeled to a specific activity of  0.051 cpm per or- 
ganism.  In this  experiment the maximum input of 3.75  x  106 
amastigotes resulted in approximately 43,600 cpm or 8.5  x  105 
organisms  bound  per  macrophage  monolayer,  for  a  binding 
efficiency of 4.4.  Background binding to blank  wells never ex- 
ceeded 350 cpm and was not subtracted. 
Given the substantial binding of leishmania amastigotes to 
L-929 cells, freshly isolated amastigotes were added to a va- 
riety of different adherent mammalian cells, and their bind- 
ing was quantitated. All cells tested, including the CHO-K1 
cell line, human foreskin fibroblasts, the human epithelioid 
cell line HEp-2, and the two murine fibroblastoid cell lines 
NIH-3T3 and L-929 (not shown), as well as murine perito- 
neal macrophages, bound leishmania amastigotes (Fig. 2). A 
single parasite-input dose was chosen to illustrate relative 
binding  efficiencies of each of the cell types in  parallel. 
Freshly isolated monocytes bound leishmania amastigotes 
least efficiently, whereas HEp-2 cells bound amastigotes al- 
most as avidly as did macrophages (Fig. 2). At a relatively 
high parasite-input dose multiple amastigotes bound to vir- 
tually every HEp-2 cell in the monolayer (Fig. 3). 
Inhibition of  Amastigote Binding by Soluble Heparin 
A  characterization of amastigote adhesion to mammalian 
cells was undertaken as a  frst step toward identifying the 
molecular basis of this interaction. The binding of amasti- 
gotes to fibroblastoid and macrophage cells was unaffected 
by treating the cells with reagents  known to inhibit other 
receptor-mediated adhesion events, including EDTA, cyto- 
chalasin,  mannan,  B-glucan, or mAbs to the macrophage 
complement receptor Mac-1 (data not shown). The adhesion 
of amastigotes to fibroblastoid and epithelioid cells, how- 
ever, was dramatically inhibited by the addition of soluble 
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Figure 2. The binding of L  amazonensis amastigotes to a variety 
of adherent  cells.  A  single dose of 2.5  x  106 L  amazonensis 
amastigotes was added to cell monolayers of human foreskin fibro- 
blasts (HFF), human epithelial cells (HEp-2), murine fibroblastoid 
cells (NIH/3T3), CHO cells (CHOKI), freshly isolated human pe- 
ripheral blood monocytes (MONO), and murine peritoneal macro- 
phages (MPM). Amastigotes were added to the monolayers in the 
absence  (~t) or presence  of 100 #g/ml heparin ([3). Binding pro- 
ceeded  for 45 rain at 35°C. Monolayers were then washed three 
times with PB, fixed, stained, and quantitated by light microscopy. 
The indicated number of  amastigotes bound to NIH-3T3 cells in the 
absence of heparin represents the average of two determinations. 
All other bars represent the mean of  triplicate determinations 5: the 
standard deviation. This experiment is representative of  three sepa- 
rate experiments. 
heparin (Fig. 2).  1 #g/ml of heparin inhibited the binding of 
L. amazonensis amastigotes to CHO-K1 cells by >90% (Fig. 
4).  This inhibition was specific,  since 500 #g/ml of chon- 
droitin sulfate was required to inhibit amastigote adhesion by 
50 %. Heparin inhibited virtually all of the binding of amasti- 
gotes to all of the nonmyeloid cells tested. In contrast to non- 
myeloid cells, the addition of heparin to macrophages did not 
Figure 3.  The binding  of L  amazonensis amastigotes to HEp-2 
cells. A single dose of 3.75 x  106 L  amazonensis amastigotes was 
added to a monolayer of  HEp-2 cells. Binding proceeded for 45 min 
at  35°C. Monolayers  were  washed three  times  with  PB,  fixed, 
stained with Giemsa dye, and examined by light microscopy. Bar, 
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Figure 4. Inhibition of L. amazonensis amastigote binding by solu- 
ble heparin.  The binding of radiolabeled L  amazonensis amasti- 
gotes to monolayers of CHO-K1 cells was measured in the absence 
(o) or presence of soluble GAGs (o,zx). Heparin was added in in- 
creasing concentrations  (o).  Chondroitin  sulfate was added at a 
single dose of 500 #g/ml (zx). Data represent the mean of triplicate 
samples + the standard deviation. The experiment is a representa- 
tive of four separate experiments. 
inhibit amastigote adhesion, regardless of the concentration 
of heparin used (Fig. 2). When amastigotes were pretreated 
with  heparin  and  washed before their  addition  to  macro- 
phage monolayers, however, a 60% inhibition of the binding 
of amastigotes to macrophages was observed (Fig.  5). 
The Binding of  Amastigotes to Cell 
Surface Proteoglycans 
Several cell-surface proteoglycans contain heparan sulfate 
GAGs. To determine whether the cell-surface heparan sul- 
fate proteoglycans were involved in amastigote adhesion,  a 
number of CHO cells with defined deficiencies in GAG bio- 
synthesis were analyzed. Increasing concentrations of leish- 
mania amastigotes were added to wild-type CHO cells and 
CHO cell lines which lacked specific GAGs (18). Organisms 
bound efficiently to wild-type CHO cells in a dose-depen- 
dent manner (Fig.  6).  In contrast to their binding to wild- 
type cells,  amastigotes failed to bind to several CHO cell 
lines with  specific deficiencies  in  GAG biosynthesis.  Two 
cell lines (pgsA-745 and pgsB-618) which express very little, 
if any, GAGs failed to bind amastigotes (Fig. 6). A third cell 
line  (pgsD-677),  which  expresses  no  heparan  sulfate but 
overexpresses chondroitin sulfate so that the total amount of 
sulfated proteoglycan present is equal to that of wild-type 
cells,  also  failed  to  bind  amastigotes.  A  fourth  cell  line 
(pgsE-606)  produces  heparan  sulfate  that  contains  about 
one-third less sulfate. These ceils bound amastigotes, albeit 
with slightly less efficiency than did the wild-type cells at the 
highest parasite-input dose tested. Thus, the binding of leish- 
mania amastigotes to CHO cells correlates with cellular ex- 
pression of proteoglycans containing heparan sulfate. 
Two  additional  approaches  were  taken  to  confirm that 
cellular  proteoglycans  are  the  ligands  for  adhesion  of 
leishmania amastigotes to mammalian cells. First, adhesion 
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Figure 5.  Inhibition  of L.  amazonensis amastigote binding by 
pretreatment with soluble heparin.  Amastigotes were pretreated 
with heparin (10 #g/mi), before their addition to monolayers of ei- 
ther MPM or HEp-2 cells. After incubation in heparin for 20 min 
on ice, the amastigotes were washed twice with PB and added to 
the monolayers at a dose of 1.25 x  106 amastigotes per well. Incu- 
bation proceeded for 45 rain at 35°C. Monolayers were washed, 
fixed, stained, and quantitated by light microscopy. Data represent 
the mean of  triplicate samples + the standard deviation from a sin- 
gle experiment representative of three. The average inhibition of 
amastigote binding to MPM from three separate experiments was 
59.4%  +  4%. 
assays were performed on HEp-2 cells which were enzy- 
matically treated with heparitinase to remove proteoglycans. 
Treatment of cells with heparitinase decreased amastigote 
adhesion in a dose-dependent manner (Fig. 7 A). Treatment 
of HEp-2 cells with 5 mlU hepadtinase decreased the adhe- 
sion of amastigotes by >70%  (Fig. 7 A). Second, adhesion 
assays were performed in the presence of  exogenous heparan 
sulfate isolated from bovine aorta. The addition of 100 #g/ml 
heparan  sulfate diminished  the  binding of amastigotes  to 
HEp-2 cells by >90%  (Fig. 7 B) and to murine peritoneal 
macrophages by ,,o40%  (Fig. 7 B). 
The Binding of12~l-labeled Heparin to 
Leishmania Amastigotes 
The inhibition of  amastigote binding to cells by soluble hepa- 
tin  or heparan  sulfate,  and the  correlation of amastigote 
binding with cellular expression of heparan sulfate suggested 
the presence ofa heparin-binding activity on amastigotes. To 
detect this activity, increasing concentrations of iodinated 
heparin were added to a constant number ofL. amazonensis 
amastigotes. Heparin bound to leishmania amastigotes in a 
dose-dependent,  specific,  and  saturable  manner  (Fig.  8). 
Scatchard analysis of these data indicates •120,000  high- 
affinity receptors, with a Ks =  8.8  x  10  -8 M.  The analysis 
also suggested a lower-affinity interaction with a Kd =  5  X 
10  -7 M. The binding of radiolabeled heparin to freshly iso- 
lated amastigotes was almost completely inhibited by excess 
nonradioactive heparin, but binding was not inhibited by ex- 
cess chondroitin sulfate or hyaluronic acid (Table I). Radio- 
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Figure 6. The binding ofL. amazonensis  amastigotes to cell-surface 
proteoglycans. Increasing numbers of L. amazonensis amastigotes 
were added to monolayers of wild-type CHO-K1 cells (o) or cells 
with specific mutations in GAG biosynthesis (o, zx, v, 0). pgsA- 
745 and pgsB-618 cells (zx, ~7, respectively) express essentially no 
glycosaminoglycans, pgsD-677 cells (D) specifically lack heparan 
sulfate but overexpress chondroitin sulfate, pgsE-606 cells (<>) ex- 
press undersulfated heparan sulfate chains. Incubation proceeded 
for 45 min at 35°C. Monolayers were washed extensively, fixed, 
stained, and quantitated by light microscopy. Data represent the 
mean of triplicate samples +  standard deviation. This experiment 
is representative of three separate experiments. 
labeled heparin also bound to a second species of leishmania 
amastigotes, L. major (Fig. 9 A). In contrast to the amasti- 
gote form, promastigotes bound heparin relatively poorly 
(Fig.  9).  The  binding  of heparin  to  either L.  major  or 
L.  amazonensis promastigotes was not detected at the low 
beparin-input  concentrations at  which  amastigotes  bound 
heparin avidly. Even at high heparin doses L. major promas- 
tigotes failed to bind heparin; however, at the highest doses 
tested (8-30 #g/ml heparin) L. amazonensis promastigotes 
bound low levels of  heparin (Fig. 9 B). The dose-dependent, 
-specific, and -saturable binding of radiolabeled heparin to 
leishmania amastigotes  is consistent with the presence of 
specific heparin-binding sites on leishmania amastigotes. 
Dot Blot Analysis 
Amastigotes were solubilized in Triton X-100,  and the ly- 
sates were analyzed for heparin-binding activity. The un- 
treated lysate bound radiolabeled heparin (Fig. 10), indicat- 
ing that it contained an intact heparin-binding activity. Like 
the activity on the intact amastigotes, radiolabeled heparin 
binding was competed with cold heparin, but not with cold 
chondroitin sulfate. The heparin-binding activity of amasti- 
gote lysates was also of high apparent affinity, because bind- 
ing occurred not only in physiological saline but also  in 
higher salt concentrations. Binding in 1 M salt was decreased 
by ,,050% relative to binding under isotonic conditions (Fig. 
10). Heparin binding occurred in SDS, as has been reported 
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Figure  7.  Inhibition  of  the  7 
binding  of  amastigotes  to 
mammalian cells.  (A) Mono- 
layers  were  pretreated  with  6 
heparitinase (0.1 mlU, []; 5.0 
mIU, I) for 2 h at 37"C and 
washed three times. A single  .--.  5 
doseof2.5  x  106 amastigotes  ~  c 
was  added  to  each  mono- 
E3  layer.  Binding  proceeded for  z  4 
45  min  at  35°C.  Monolay-  o 
ers  were washed,  fixed,  and  m 
z 
stained. Adhesion was quanti-  ~  3 
< 
tated by light microscopy. (B)  ~- 
LO 
Soluble  glycosaminoglycans  z 
were used to  inhibit  amasti-  2 
gote binding.  A single dose of 
2.5  x  10  6  amastigotes  was 
added to monolayers of either  1 
HEp-2 cells or MPM. Binding 
proceeded  either  in  the  ab- 
sence  (o)  or  presence  of  0 
heparan sulfate ([])  or hepa- 
fin (-) at a concentration of 
100/~g/ml. Amastigote adhe- 
sion  was  quantitated  as  de- 
scribed above.  Data represent 
the mean of triplicate samples 
+  standard deviation. 
for other heparin-binding  proteins (5).  Treatment of the ly- 
sate with the reducing agent 2-mercaptoethanol or with tryp- 
sin  completely  abolished  heparin  binding,  suggesting  that 
the binding  activity was most likely mediated by a  protein 
on the surface of amastigotes. 
O,2J+S+ 
B 
q  I  I  I 
I  2  3  4 
125 
I-HEPARIN  ADDED  (,u.M) 
Figure & Radiolabeled heparin binding to L. mnazonensis amas- 
tigotes. Increasing amounts of radiolabeled heparin (sp act =  3.1 
×  105 cpm//~g) were added to a constant number (2  x  107) of L. 
amazonensis amastigotes. Organisms were incubated for 30 min at 
4°C and washed three times. The amount of 125I-labeled heparin 
bound to the parasites was determined.  A  Scatchard plot of the 
binding data (inset) shows two lines. From the slope and x intercept 
of the first line,  a binding constant (Kd) of 8.8  x  10  -s M  and a 
stoichiometry of 120,000 receptors per organism were determined. 
From the second line, a Kd of 5.0  X  10  -7 and a stoichiometry of 
210,000  receptors per organism were determined. Data represent 
the average of two determinations. This experiment is representa- 
tive of three separate experiments. 
Discussion 
Amastigotes  are  the  developmental  form  of  leishmania 
which  exists  within  mammalian  cells.  They  multiply  in- 
tracellularly  and  spread  the  disease  to  neighboring  cells. 
Very little  is  known  about  how  amastigotes  interact  with 
mammalian cells. Neither the receptors on mammalian cells 
involved in mediating amastigote adhesion nor the ligand(s) 
on  amastigotes  with  which  mammalian  cells  interact  is 
known.  In this report, we present several lines of evidence 
that are consistent with a heparin-binding  activity being an 
adhesion  factor  for  leishmania  amastigotes.  Adhesion  of 
amastigotes to cells was inhibited by the addition of exoge- 
nous GAGs. The addition of micromolar amounts of heparin 
abolished the binding of amastigotes to several mammalian 
cells, including CHO ceils, human foreskin fibroblasts, and 
HEp-2 cells.  This inhibition was specific to heparin,  since 
other GAGs, such as chondroitin sulfate or hyaluronic acid, 
did  not  inhibit  amastigote  adhesion  to  these  cells  unless 
added at a  500-fold higher molar concentration.  The addi- 
tion of intact heparan  sulfate proteoglycans  also  inhibited 
adhesion of amastigotes to mammalian cells. Pretreatment of 
amastigotes with heparin  prior to their addition to HEp-2 
cells  or  to  macrophages  resulted  in  decreased  amastigote 
binding,  indicating that the heparin-binding  activity resides 
on the amastigote and not on the mammalian cell. Addition- 
ally, the removal of cellular heparan sulfate by pretreatment 
of mammalian cells with heparitinase resulted in decreased 
adhesion of arnastigotes to these cells,  indicating that cell- 
surface  heparan  sulfate  proteoglycans  are  the  ligands  for 
amastigote adhesion.  Finally,  amastigotes fail to adhere to 
three CHO cell lines with single, defined mutations in hepa- 
ran  sulfate biosynthesis.  These mutant CHO cell lines ex- 
press  low  or  absent  levels  of heparan  sulfate.  However, 
amastigotes bound efficiently to the parent CHO cell line and 
to  a  cell  line  with  undersulfated  heparan.  Even  heparan 
sulfate-deficient cells which express the same amount of sul- 
Table L  Inhibition of Radiolabeled Heparin 
Binding to L.  amazonensis Amastigotes by 
Soluble Glycosaminoglycans 
Competitor*  cpm bound*  Hepariu bound* 
(ng) 
None  18,385  4- 2,770  94  4-  14 
Heparin  2,494  +  1,212  13  +  6 
Chondroitin sulfate  19,010  +  4,507  97  4- 23 
Hyaluronic acid  15,921  4-  1,046  81  4- 5 
* Unlabeled competitors were used at a final concentration of 1.6 mg/ml. 
* The amount of radiolabeled  heparin bound per 2  x  l0  T amastigotes. Values 
represent the mean +  SD of triplicate  determinations. 
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Figure 9.  Binding of radiola- 
beled heparin to L. major (A) 
and L. amazonensis (B) amas- 
tigotes and promastigotes. (A) 
Radiolabeled heparin  (sp act 
=  1.96  ×  1@ cpm/#g)was 
added to freshly  isolated  L  ma- 
jor amastigotes (o) or station- 
ary-phase promastigotes (e). 
Parasites  were  washed three 
times with PB supplemented 
with 1% BSA, and the amount 
of m25I-labeled heparin bound 
to  the  parasites  was  deter- 
mined.  Data  represent  the 
mean of three determinations 
+  standard deviation. (B) In- 
creasing amounts of radiola- 
beled heparin (sp act = 4.0 x 
106  cpm/#g)  were  added  to 
freshly isolated L. amazonen- 
sis amastigotes (o) or station- 
ary-phase promastigotes (•). 
Free 125I-labeled heparin was 
separated  from  bound  t25I- 
labeled  heparin  by  pelleting 
the parasites through an oil gradient (see Materials and Methods). 
Data represent the average of two determinations. This experiment 
is representative of three separate experiments. 
fated proteoglycan, due to the overexpression of chondroitin 
sulfate, failed to bind amastigotes. 
The leishmania heparin-binding activity is expressed on 
intact organisms, and it was also detected in amastigote ly- 
sates. Intact amastigotes ofL. amazonensis bound an average 
of approximately 120,000 molecules of heparin, with an ap- 
parent affinity of 8.8  x  10  -8 M.  Amastigotes of a  second 
species of leishmania, L.  major, also expressed a heparin- 
binding activity. We were unable to detect this high-affinity 
activity on the promastigote form of either species. In our 
hands,  promastigotes bound  heparin  poorly compared to 
amastigotes.  Others  have  previously  identified  a  lower- 
affinity, heparin-binding activity on promastigotes of Leish- 
mania donovani (4). We have not examined that species, but 
we speculate that the activity on promastigotes is distinct 
from the high-affinity activity described here on amastigotes. 
As we do detect some binding of heparin to promastigotes 
at high heparin input concentrations, this low-affinity bind- 
ing of  heparin to promastigotes may correspond to the lower- 
affinity activity detected on amastigotes.  The Kd value for 
this  second activity  (5  x  10  -7  M)  approximates  that  re- 
ported for L.  donovani promastigotes (4). Importantly, the 
low-affinity activity on promastigotes does not appear to be 
essential for parasite binding to cells. Promastigotes bound 
very poorly to epithelioid and fibroblastoid cell lines which 
express proteoglycans and which bound amastigotes avidly 
(data not shown). Furthermore, in contrast to amastigotes, 
the addition of excess soluble heparin has been reported to 
actually enhance the  binding  of promastigotes to  macro- 
phages (4). 
We hypothesize that the binding of amastigotes to beparan 
sulfate proteoglycans is an important first step in the invasion 
of  mammalian cells. We demonstrate that leishmania amasti- 
gotes bind to several different types of mammalian cells in 
Figure 10.  Heparin-binding activ- 
ity of L.  amazonensis  amastigote 
lysates. 5 #l of amastigote lysate 
(see Materials and Methods) was 
added to nitrocellulose after vari- 
ous experimental treatments,  and 
the heparin-binding activity of the 
lysates was examined. Blots were 
probed  with  nSI-labeled heparin, 
washed extensively, air dried, and 
analyzed  on  a  Fuji  Bioimager. 
Blots were exposed to bioimaging 
plates  for  1  h.  Incubation  with 
125I-labeled  heparin  was  per- 
formed in the presence of: (A) no 
competitor;  (B) 200  #g/ml  unla- 
beled  heparin;  (C)  200  gg/ml 
chondroitin sulfate; and (D)  1 M 
NaC1. The amastigote lysates were 
also treated in the following ways 
before addition to the  nitrocellu- 
lose: (E) boiling the lysate in the 
presence  of  5%  2-mercaptoeth- 
anol; (F) boiling the lysate in the 
presence of 0.1% SDS; and (G) in- 
cubation with  100 /zg/ml TPKC- 
treated trypsin for 15 min at 37°C. 
As  a  negative control,  (H)  100 
pg/ml BSA was added to the nitro- 
cellulose and incubated with  125I- 
labeled heparin.  This experiment 
is representative of three separate 
experiments. 
vitro. These cells include phagocytic macrophages as well as 
the nonphagocytic fibroblastoid and  epithelioid cells.  Al- 
though the macrophage has long been considered a focus for 
the intracellular replication of leishmania, these epithelioid 
and fibroblastoid cells may be an important reservoir for this 
organism. Indeed, several in vivo studies have demonstrated 
the presence of intact parasites within nonmacrophage cells 
(32). We have begun to examine the efficiency with which 
leishrnania  amastigotes  are taken  up by these  nonmacro- 
phage cells in vitro and the extent to which amastigotes sur- 
vive within these cells. 
The efficient and almost complete inhibition of  the binding 
of amastigotes to nonmyeloid cells by soluble heparin sug- 
gests that the cell surface proteoglycans are the principal, if 
not sole, mechanism used by amastigotes to adhere to fibro- 
blastoid and epithelioid cells. The recognition of  amastigotes 
by macrophages, however, may be more complex than the 
relatively  simple  mechanism  used  by  nonmyeloid cells. 
Soluble  heparin  inhibits  amastigote  adhesion  to  macro- 
phages by only 60%,  and this inhibition is only observed 
when the amastigotes are pretreated with heparin prior to 
their addition to macrophages. Cellular beparan sulfate in- 
hibits amastigote adhesion to macrophages by only 40%, and 
amastigote adhesion was not affected by treatment of macro- 
phages with heparitinase (data not shown). We speculate that 
the  inability  to  completely inhibit  amastigote  binding  to 
macrophages reflects the participation of additional cellular 
mechanisms  by which macrophages  recognize leishmania 
amastigotes.  These additional mechanisms may cooperate 
with the proteoglycan interaction and promote more efficient 
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reported to mediate the binding of cytomegalovirus to mam- 
malian cells (9).  Cytomegalovirus adheres to cell-surface 
proteoglycans (25), but efficient invasion of cytomegalovirus 
into mammalian cells is dependent on additional cellular 
receptors. In fact, we observed that macrophages internalize 
amastigotes much more efficiently than do the nonmyeloid 
cell lines that we have examined (A.  Brittingham, D.  C. 
Love, and D. M. Mosser, manuscript in preparation). This 
finding would be consistent with the hypothesis that efficient 
amastigote internalization requires the cooperation of more 
than one type of receptor. 
In summary, we have identified a heparin-binding activity 
on leishmania amastigotes.  The  expression of this  activ- 
ity correlates with the ability of amastigotes to adhere to 
mammalian cells which express  proteoglycans containing 
heparan sulfate. We hypothesize that amastigotes use this 
heparin-binding activity to facilitate their interaction with 
mammalian cells. Studies are underway to isolate the mole- 
cule(s) mediating this activity and to determine its role as a 
leishmania virulence factor. 
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